Table 2. Analysis of Lymphoma and... | American Society of Hematology

Table 2.

Analysis of Lymphoma and Lymphoproliferative Disease According to Type of Match and Method of T-Cell Depletion

Method of Lymphocyte Depletion of Donor	HLA-Identical Sibling Donors			Other Donors
Method of Lymphocyte Depletion of Donor	Total No. of Patients	Rejection Prophylaxis With CAMPATH-1G	Cases of Lymphoma	Total No. of Patients	Rejection Prophylaxis With CAMPATH-1G	Cases of Lymphoma
None	62	62	0	82	82	0
CAMPATH-1 in vitro (complete depletion)	1,019	332	8 (1.3%)^*	622	479	5 (1.3%)
CAMPATH-1 in vitro (with T-cell addback)	258	31	0	45	30	0
CAMPATH-1 in vivo	84	84	0	374	374	2 (0.9%)
E-rosette	0	NA	NA	20	20	5 (29.0%)^†
Other methods	6	6	0	10	10	0

Method of Lymphocyte Depletion of Donor	HLA-Identical Sibling Donors			Other Donors
Method of Lymphocyte Depletion of Donor	Total No. of Patients	Rejection Prophylaxis With CAMPATH-1G	Cases of Lymphoma	Total No. of Patients	Rejection Prophylaxis With CAMPATH-1G	Cases of Lymphoma
None	62	62	0	82	82	0
CAMPATH-1 in vitro (complete depletion)	1,019	332	8 (1.3%)^*	622	479	5 (1.3%)
CAMPATH-1 in vitro (with T-cell addback)	258	31	0	45	30	0
CAMPATH-1 in vivo	84	84	0	374	374	2 (0.9%)
E-rosette	0	NA	NA	20	20	5 (29.0%)^†
Other methods	6	6	0	10	10	0

Abbreviation: NA, not applicable.

The actuarial risk at 2 years posttransplant of developing lymphoma or BLPD was calculated by life table analysis.

The result for E-rosette depletion is significantly different from CAMPATH-1 depletion (P < .0001).